| Literature DB >> 35260714 |
Orr Shomroni1, Maren Sitte1, Julia Schmidt2, Sabnam Parbin1, Fabian Ludewig1, Gökhan Yigit2,3, Laura Cecilia Zelarayan4,3, Katrin Streckfuss-Bömeke5,3,6, Bernd Wollnik2,3,7, Gabriela Salinas8.
Abstract
Single cell multi-omics analysis has the potential to yield a comprehensive understanding of the cellular events that underlie the basis of human diseases. The cardinal feature to access this information is the technology used for single-cell isolation, barcoding, and sequencing. Most currently used single-cell RNA-sequencing platforms have limitations in several areas including cell selection, documentation and library chemistry. In this study, we describe a novel high-throughput, full-length, single-cell RNA-sequencing approach that combines the CellenONE isolation and sorting system with the ICELL8 processing instrument. This method offers substantial improvements in single cell selection, documentation and capturing rate. Moreover, it allows the use of flexible chemistry for library preparations and the analysis of living or fixed cells, whole cells independent of sizing and morphology, as well as of nuclei. We applied this method to dermal fibroblasts derived from six patients with different segmental progeria syndromes and defined phenotype associated pathway signatures with variant associated expression modifiers. These results validate the applicability of our method to highlight genotype-expression relationships for molecular phenotyping of individual cells derived from human patients.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35260714 PMCID: PMC8904555 DOI: 10.1038/s41598-022-07874-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Technical information of state-of-the-art integrated platforms for single-cell RNA-Sequencing. Methods used in each of the platforms for single-cell isolation, barcoding, chemistry and sequencing. (a) the 10× Genomics Chromium (b) the ICELL8 cx Single-Cell system; ICELL8 (c) the CellenONE X1 system, CellenONE and (d) advantages of the combined CellenONE X1 and iCELL8 cx Single-Cell systems, CellenONE-ICELL8.
Figure 2Study design for the scRNA-Seq approaches validation. (a) Experimental design for the CellenONE-ICELL8 Single-Cell System combination. Only one ICELL8 nano-well chip was used for all eight dermal fibroblasts patient samples. (b) Experimental design for the ICELL8 Single-Cell System. A total of three (3) ICELL8 nano-well chips were used for all eight dermal fibroblasts patient samples. (c) Bar plot displaying proportions of reads left in both single-cell methods after each step of the analysis. (d) Venn diagram displaying the number of genes in QC-filtered data from both approaches and the violin plot shows the number of QC-filtered genes expressed in individual cells in both approaches.
Number of cells dispensed and selected for sequencing after QC-filtering data set (CogentDS).
| GOE1303 | GOE1305 | GOE1309 | GOE1360 | GOE247 | GOE486 | GOE615 | |
|---|---|---|---|---|---|---|---|
| No. of cells dispensed | 576 | 576 | 576 | 576 | 576 | 576 | 576 |
| No. of cells Post-QC | 387 | 295 | 298 | 537 | 479 | 195 | 218 |
| Total cells Post-QC | 3135 | ||||||
| No. of cells dispensed | 436 | 364 | 485 | 356 | 446 | 477 | 350 |
| No. of cells Post-QC | 423 | 323 | 411 | 280 | 386 | 445 | 317 |
| Total cells Post-QC | 3129 | ||||||
Read parameters of the two scRNA-seq approaches CellenONE-ICELL8 and ICELL8 (CogentDS).
| QC-Parameters | CellenONE-ICELL8 | ICELL8 |
|---|---|---|
| Samples | 8 | 8 |
| No. of cells | 5184 | 3616 cells |
| No. of cells Post-QC | 3135 | 3129 cells |
| Total Reads | 1.67G | 1.01 G |
| Barcoded Reads | 1.61G | 985 M |
| Fraction Barcoded Reads | 0.96 | 0.98 |
| Barcodes Identified | 5184 cells | 3616 cells |
| Reads per Barcode | 309.84 K | 272.54 K |
| Barcoded Reads | 1606229682 (100%) | 985522031 (100%) |
| Trimmed Reads | 1601535800 (99.71%) | 982927397 (99.74%) |
| Unmapped Reads | 86672148 (5.4%) | 16885303 (1.71%) |
| Mapped Reads | 1514863652 (94.31%) | 966042094 (98.02%) |
| Uniquely Mapped Reads | 1270205342 (79,08%) | 778278333 (78.97%) |
| Multimapped Reads | 244658310 (15,23%) | 187763761 (19.05%) |
| Total Exon Reads | 788938677 (49,12%) | 727757440 (73.84%) |
| Unique Exon Reads | 714643829 (44.49%) | 654119292 (66.37%) |
| Ambiguous Exon Reads | 74294848 (4.63%) | 73638148 (7.47%) |
| Total Intron Reads | 337929018 (21.04%) | 37383326 (3,79%) |
| Unique Intron Reads | 300416455 (18,7%) | 32630018 (3.31%) |
| Ambiguous Intron Reads | 37512563 (2.34%) | 4753308 (0.48%) |
| Intergenic Reads | 143337647 (8.92%) | 13137567 (1.33%) |
| Mitochondrial Reads | 93167354 (5.8%) | 57107478 (5.79%) |
| Ribosomal Reads | 30369153 (1.89%) | 29861198 (3.03%) |
RNA-Biotype percentages identified in sample GOE1309 using the CellenONE-ICELL8 and ICELL8 methods.
Figure 3Correlations of scRNA-Seq methods and bulk RNA-seq. (a) Natural-log-scaled ranks of top 100 markers in each sample from both single-cell approaches, including a regression line with 95% confidence interval (in gray) and the overall correlation coefficient R. (b) Correlations of normalised expressions of the top 100 markers in sample GOE247 between both single-cell and bulk RNA-seq, with the correlation coefficients indicated in the upper triangle. (c) Venn diagram of all markers detected for sample GOE247 in both approaches.
Figure 4Analysis of transcriptional heterogeneity of dermal fibroblast derived from patients using the novel platform. (a) t-SNE of the ICELL8 and CellenONE-ICELL8 experiments. (b) Circo plot showing connection of top 100 marker genes of the samples in both ICELL8 and CellenONE-ICELL8 platforms. (c) Unsupervised t-SNE of the CellenONE-ICELL8 approach. (d) t-SNE showing most prominent markers for different clusters. (e) Heatmap of rank scores of the top 30 markers in each unsupervised cluster, including enriched pathways.
Overview of mutations detected in the scRNA-seq and bulk RNA-seq.
| Sample | Gene | dbSNP | Chr | Position | Genotype | Codon | Protein | Variant name |
|---|---|---|---|---|---|---|---|---|
| GOE615 | DAXX | rs146304558 | 6 | 33,320,019 | 1/1 | c.1457C > G | p.Ala486Gly | DAXXA486G |
| GOE247 | MRPL34 | rs201529220 | 19 | 17,306,321 | 0/1 | c.221C > T | p.Ala74Val | MRPL34A74V |
| GOE800 | MT-CO1 | rs202216551 | M | 6267 | 1/1 | m.6267G > A | p.Ala122Thr | MT-CO1A122T |
| GOE1309 | MT-ND4 | rs2853494 | M | 11,641 | 1/1 | m.11641A > G | p.Ile294Met | MT-ND4I294M |
| GOE486 | MT-ND5 | NA | M | 12,557 | 1/1 | m.12557C > T | p.Thr74Ile | MT-ND5T74I |
| GOE1360 | MT-CYB | rs193302994 | M | 15,452 | 1/1 | m.15452C > A | p.Leu236Ile | MT-CYBL236I |
Figure 5Analysis of mutational heterogeneity in dermal fibroblast derived patients. (a) tSNE plot showing cells classified according to their sample affiliation. (b) t-SNE projection showing non-uniformly distributed DAXXA486G variant-expressing cells in patient GOE615 in red and the regulon for variant-dependent genes. The heatmap displays the scaled, normalized gene expressions of the top 30 markers with highest adjusted p values from the regression of the gene expressions to the mutation rate (p values shown in top bar), and a bar graph on the left shows mutant cell fraction in each cluster labelled to the left of the heatmap. (c) t-SNE projection showing non-uniformly distributed MT-CYBL236I variant-expressing cells in GOE1360 in red and the regulon for variant-dependent genes, with a bar graph showing mutant cell fraction in each cluster labelled to the left of the heatmap.
Figure 6Variant-associated expression signatures in GOE615 and GOE1360. (a) Heatmaps showing log2FC and- log10 of adjusted p value for genes differentially expressed in mutant vs nonmutant cells for DAXXA486G variant in sample GOE615 related to protein–protein interaction showing phenotype (StringDB) and pathways (Reactome) for this specific variant. (b) Heatmaps showing log2FC and- log10 of adjusted p value for genes differentially expressed in mutant vs non-mutant cells for MT-CYBL236I variant in sample GOE1360 related to protein–protein interaction showing phenotype (StringDB) and pathways (Reactome) for this specific variant.